Plandai Biotechnology Sets for Battle Against Neurological Diseases by using Nutraceuticals
Plandaí Biotechnology, Inc. (OTCQB: PLPL) transforming the world of nutraceuticals by making available extracts from live plant material that deliver the highest levels of bioavailability currently in the market. These extracts are utilized to deliver a new family of drugs to safely and cost effectively treats a plethora of different diseases and conditions.
Read more »
Acadia Forges Forward With Pimavanserin
On March 12, 2013, Acadia Pharmaceuticals (ACAD) reported financial results for the fourth quarter and full year 2012. Total revenues in the quarter were $0.4 million, essentially in-line with our estimate of $0.3 million. Revenues consisted of collaborative payments from Allergan, Inc. (AGN) and other collaboration partners. For the full year 2012, total revenues were $4.9 million.
Read more »Acadia and Biovail Not Giving Up on Parkinson’s Drug
Acadia and its partner Biovail made news last month with a failed late-stage trial of pimavanserin, their experimental drug candidate to treat psychosis related to Parkinson’s disease.
Read more »Burrill Report: Financing Activity May Lift Cloud Hanging Over Biotech Industry
While biotech leaders from all over the world gathered at the 2009 BIO International Convention in Atlanta, financing activity in the sector raised hope that the cloud hanging over the industry may be lifting a little.
Read more »